INTRODUCTION: This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy. PATIENTS AND METHODS: A retrospective evaluation of reproductive hormones in patients with unilateral stage I TGCC (N=72) without relapse diagnosed between 1990 and 2008. A group of healthy males (N=706) served as controls. RESULTS: Before orchiectomy there were no significant differences in luteinizing hormone (LH) and testosterone (T) levels between human chorionic gonadotropin (hCG)-negative patients and controls, although 33% of the patients were outside the 97.5 percentile when using bivariate LH/T evaluation. At 1-year follow-up there was a significant increase in LH (ΔLH=2.04IU/L, p<0.001), and 57% of the patients had an LH/T relation outside the 97.5 percentile. CONCLUSION: Patients with stage I TGCC are at increased risk of having an LH/T relation outside the normal range one year after orchiectomy, suggesting insufficient Leydig-cell function. Whether a proportion of these patients will develop manifest hypogonadism and benefit from androgen therapy is yet to be clarified.
INTRODUCTION: This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy. PATIENTS AND METHODS: A retrospective evaluation of reproductive hormones in patients with unilateral stage I TGCC (N=72) without relapse diagnosed between 1990 and 2008. A group of healthy males (N=706) served as controls. RESULTS: Before orchiectomy there were no significant differences in luteinizing hormone (LH) and testosterone (T) levels between human chorionic gonadotropin (hCG)-negative patients and controls, although 33% of the patients were outside the 97.5 percentile when using bivariate LH/T evaluation. At 1-year follow-up there was a significant increase in LH (ΔLH=2.04IU/L, p<0.001), and 57% of the patients had an LH/T relation outside the 97.5 percentile. CONCLUSION:Patients with stage I TGCC are at increased risk of having an LH/T relation outside the normal range one year after orchiectomy, suggesting insufficient Leydig-cell function. Whether a proportion of these patients will develop manifest hypogonadism and benefit from androgen therapy is yet to be clarified.
Authors: Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Ali Amidi; Lisa M Wu; Anders Degn Pedersen; Mimi Mehlsen; Christina Gundgaard Pedersen; Philip Rossen; Mads Agerbæk; Robert Zachariae Journal: Support Care Cancer Date: 2015-02-26 Impact factor: 3.603
Authors: Cecilie R Buskbjerg; Robert Zachariae; Mads Agerbæk; Claus H Gravholt; Lene Haldbo-Classen; S M Hadi Hosseini; Ali Amidi Journal: Brain Imaging Behav Date: 2021-08-15 Impact factor: 3.978
Authors: Natasha N Frederick; Vicky Lehmann; Astrid Ahler; Kristen Carpenter; Brooke Cherven; James L Klosky; Leena Nahata; Gwendolyn P Quinn Journal: Pediatr Blood Cancer Date: 2021-12-06 Impact factor: 3.838
Authors: Pawel J Wiechno; Grazyna M Poniatowska; Wojciech Michalski; Jakub Kucharz; Malgorzata Sadowska; Joanna Jonska-Gmyrek; Karol Nietupski; Joanna Rzymowska; Tomasz Demkow Journal: Med Oncol Date: 2017-06-01 Impact factor: 3.064